Recent Finacing
Recent Raise
Telomere Therapeutics develops an in vivo gene therapy targeting telomeric syndromes such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita, and to mitigate SARS‑CoV‑2–exacerbated severity.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Telomere Therapeutics.
